Introduction
The basis of phenotypic diversity and treatment failure in human GB is poorly understood. Murine models of gliomagenesis point to sub-ependymal neural stem cells (NSCs) as a putative cell of origin for astrocytic tumors. The stepwise pre-malignant loss of tumor suppressors p53, NF1 & PTEN (1, 2) has been shown to lead to the development of an aggressive disease characterized by resistance to genotoxic injury (3).
Additionally, stratifying patients using transcriptional profiles derived from a large cohort of GB single tumor samples (4) has identified multiple disease subtypes, which may have prognostic significance (5, 6) . However, emerging data on genomic intra-tumor heterogeneity in GB indicate spatial segregation of genetically distinct clones in the same tumor (7) , making the interpretation of single-sample tumor data challenging. Importantly, this may contribute to the pervasive failure of treatment in GB patients.
Clinical trials have established that use of a fluorescence biomarker, 5-aminolevulinic acid (5-ALA), can enhance the surgical resection of GB (8) . We have demonstrated the use of 5-ALA in a Fluorescence-Guided Multiple Sampling (FGMS) strategy that permits real-time spatially segregated tumor sampling during surgery (7, 9) . Combining visible fluorescence with neuroanatomy allows for the objective distinction of the tumor mass T (visible fluorescent). Importantly, a spatially distinct and visibly fluorescent sub-ependymal zone (SEZ) can also be identified in a subset of GB patients.
Here we report an integrated genomic analysis of SEZ and T samples, obtained by FGMS, which reveals that malignant cells in the SEZ contribute to tumor growth. Functional characterization confirms that the SEZ contains tumor-initiating cells (TICs) that can recapitulate the disease in orthotopic patient-derived xenogeneic models in a manner similar to TICs isolated from the 4 corresponding T. TICs in the SEZ contribute to resistance to chemotherapy and show differential patterns of response when compared to T of the same patients.
Materials and Methods

GB sample collection
Patient informed consent was obtained through our research clinic (10) 
Quantitative Real-time PCR analysis
Total RNA was extracted from T and SEZ tissues using TRIzol (Invitrogen) according to the manufacturer's instructions. RNA was treated with DNase (Qiagen) and cDNA was synthesized from 5μg of total RNA using Random Primers (Invitrogen) and a Superscript III First-Strand Synthesis System for real-time PCR (RT-PCR) (Invitrogen). The RT-PCR for Nestin, Gfap, Sox2 and MIB1 transcripts was performed using CFX96 RT-PCR (Biorad), RT 2 qPCR Primer Assay and SYBR Green Master Mix (Qiagen) according to the manufacturer's instructions. 18S was used as the housekeeping reference. Relative expression quantification was performed by the ΔΔCT method. Experiments were performed in triplicate and each experiment was repeated 3 times.
Cell line derivation and implantation
Cell cultures from T and SEZ of 42 patients were established from GB patients undergoing surgery at Addenbrooke's Hospital, Cambridge, in 2010-2012. The cells were isolated as described (9, 11, 12) and used either uncultured (primary) or propagated in vitro for 2 passages (briefly cultured) in serumfree medium. The U87 cell line was obtained from the American Type Culture Collection, cultured according to the supplier's recommendations and used just after resuscitation. Tissue collection to establish HFNSCs was approved by the Local Regional Ethics Committee. Cells were established in 2011 and grown in serum-free medium in order to form neurospheres and used at early passage. All the cell cultures have been tested for mycoplasma contamination by PCR before use. See Supplementary Experimental Procedure for details on cell propagation, immunofluorescence and in vivo experiments.
DNA and RNA extraction
DNA from T and SEZ tissues of 14 GB patients was extracted for copy number analysis using DNeasy Blood & Tissue Kit (Qiagen). RNA from T and SEZ tissues of 15 GB patients was extracted for gene expression analysis using Trizol (Invitrogen) and cleaned up using MiniElute columns (Qiagen). See
Supplementary Experimental Procedure for details on copy number and gene expression analysis. Copy number results were validated by fluorescence in situ hybridization as described in the Supplementary Experimental Procedure.
Drug treatment assay
Treatment with Temozolomide, Cisplatin and Cediranib was evaluated using the in vitro BrdU cell proliferation assay (Millipore). 3x10 
MGMT promoter methylation
Analysis of MGMT promoter methylation was performed by PCR (13) and by pyrosequencing (14) . In brief, DNA was bisulfite converted and subsequently subjected to PCRs using specific primer pairs for the methylated or the modified unmethylated DNA. PCR products were resolved in a 2% agarose gel stained with SybrSafe. See Supplementary Experimental Procedure for further details.
Phylogenetic reconstruction
Multiple spatially separated samples taken from each GB were collected in order to reconstruct the phylogenetic relationship between the tumor and SEZ. See Supplementary Experimental Procedure for details on molecular clock analysis.
Statistical analysis
For in vivo experiments using Nod/Scid animals, we performed Kaplan-Meier survival analysis using the Logrank test for hypothesis testing.
For drug response analysis using BrdU, a one-way ANOVA was performed for each patient.
The p-values for the pairwise mean comparisons of each treatment to the corresponding control were calculated using Tukey's Honestly Significant Difference test. In the related figures and for each patient, we plotted the normalized mean treatment response using the corresponding mean control as a reference, except in Supplementary Fig. 12 , where we normalized to the mean of the 50µM TMZ treatment response. The minimum and maximum normalized values are provided in order to present the dispersion of the normalized data.
Results
SEZ harbors residual disease in GB patients
We screened 65 GB patients given 5-ALA and confirmed that visibly fluorescent disease extended to the SEZ in 65% (42/65) of the cases. Multiple samples were obtained from 14 patients. Histological features of high-grade glioma (15) were detected in SEZ and T of the patients ( Fig. 1A ; additional two representative GBs are shown in Supplementary Fig. S1 , A and B). SEZ tissue was also used to identify the ependymal layer and confirm correct sampling ( Supplementary Fig. S2 ).
GB has been shown to heterogeneously express glial fibrillary acidic protein (Gfap) (16) and consistent with this we noted high expression of Gfap in SEZ samples compared to matched T samples (Fig. 1, B and C top panel and Supplementary Fig. S1C ). Expression of the precursor marker Nestin was detected both in T and SEZ tissues (Fig. 1 , B and C middle panel and Supplementary Fig. S1C ). The SEZ showed increased vascularization in comparison to T, as determined by CD31 expression (Fig. 1 , B and C bottom panel). Weak expression of the neuronal marker Tuj1 was observed in both areas ( Supplementary Fig. S1C ). One of the histological hallmarks of GB is high proliferative activity (17) and we observed similar numbers of mitotic cells in T and SEZ (MIB1 index 20.5±2.8 and 18.1±1.9 respectively) ( Supplementary Fig. S1C ). The extent of focal necrosis was similar in T and SEZ of the same patients (except for sp40) (Supplementary Table S1 ). Consistent with immunohistochemical analysis, T and SEZ contained similar amounts of tumor tissue (except for sp54) (Supplementary Table   S1 ). Together these data suggest that regulatory mechanisms promoting proliferation and vascularization are common to the T and the SEZ tissues. is similar between T and SEZ, except in sp10 for Sox2 ( Supplementary Fig. S3 ).
We applied high-throughput molecular profiling techniques to the SEZ and T to characterize each of these regions. DNA/RNA were extracted from the tissues of the 14 patients (Supplementary Table   S2A ). After quality assessment, we analyzed copy number aberrations (CNAs) of 8 patients and gene expression profiles of 9 patients (6 of whom were common to both analyses) (Supplementary Table   S2B shows the patient clinical information). Our data reveal multiple aberrations (e.g. EGFR amplification and CDKN2A deletions) common to T and the corresponding SEZ in individual patients 8 ( Fig. 2A and Supplementary Fig. S4 ). In 6/8 patients, the SEZ had an equal or smaller number of putative driver aberrations with respect to the corresponding T (mean difference in the number of aberrations is 1.27±0.38; p-value = 0.12). CNA results were validated by fluorescence in situ hybridization (FISH) for three GB drivers, EGFR, MET and PTEN (4), in three patients with available tissue (Fig. 2B and Supplementary Fig. S5, A-H) . Because we observed in vitro aberrations in the corresponding cell cultures ( Supplementary Fig. S6 ), we restricted further genomic analysis to tissue samples.
Clustering of the gene expression data (18) revealed that only 3/9 paired samples (SEZ and T from the same patient) clustered tightly together while 5/9 SEZ were assigned to the same sub-cluster, suggesting a SEZ-specific expression profile across patients (Fig. 2C ).
We used a previously published classifier to assign our samples into one of 4 GB subtypes (6). 7/9 SEZ were classified as Mesenchymal (sp41, sp42, sp52, sp54, sp56, sp57 and r4) and the remaining 2 were Classical (sp49 and sp55). For 6/9 patients the SEZ was assigned to a different subtype than the corresponding T. T samples were distributed amongst the 4 subtypes (Classical, Mesenchymal, Neural and Proneural) (Fig. 2D) .
We next investigated whether gene expression levels differed between SEZ and T. We rejected the hypotheses of no significant differences in the expression levels of all genes between SEZ and T (pvalue <0.00001), which suggests that there are differentially expressed genes in SEZ and T.
We next used the R package HDTD to identify gene ontology (GO) terms whose genes are differentially expressed (Supplementary Table S3 ).
Tumor-initiating cells reside in the SEZ
We next extended the characterization of T and SEZ to TIC populations. In neuro-epithelial malignancies the purification of TICs remains challenging because no robust cell-surface marker has been identified to distinguish tumorigenic and non-tumorigenic cells (19, 20) . Initial data identifying CD133/Prominin1 as a marker in human GB (21) were subsequently challenged both in primary and cultured TICs (reviewed in (19) ). More recently the cell surface marker CD15/SSEA-1 has been identified as a possible TIC marker in GB and medulloblastoma (22, 23) . CD15 is a carbohydrate moiety expressed by neural stem and progenitor cells (24) but its use as GB marker did not find additional confirmation (25) .
We therefore used a marker-independent approach (9, 11, 12, 26) to isolate cells from T and SEZ under serum-free conditions in vitro (Fig. 3A) . Growth curve analysis and limiting-dilution assays confirmed long-term self-renewal and expansion ( Fig. 3B and Supplementary Fig. S7 ), clonogenicity and multipotency similar to the corresponding T cells (Supplementary Fig. S8 ).
We evaluated the expression of the precursor marker Nestin and other putative TIC markers (A2B5, CD133, CD15) from T and SEZ (reviewed in (19) ) and found similar expression of Nestin in T and SEZ cells, in agreement with the data in Fig. 1 , B and C. In contrast, A2B5-, CD133-and CD15-positive cells were rarely found ( Supplementary Fig. S9, A and B) .
Despite phenotypic differences in vitro, orthotopic inoculation of T and SEZ cells in NOD-SCID mice consistently generated tumors in all cases (Fig. 3, C and D and Supplementary Fig. S10 ). Nonetheless, a statistically significant shorter survival was observed for animals injected with T cells compared to those injected with SEZ cells (Fig. 3C and Supplementary Fig. S10 ; p-value <0.05).
To our knowledge, this is the first time that SEZ cells from GB patients have been tested for their tumorigenic potential. We analyzed the in vivo properties of enriched SEZ cells from 3 additional GBs.
In all cases SEZ cells gave rise to tumors with similar patterns of growth and infiltration to those generated from TICs isolated from T under the same experimental conditions (Supplementary Fig. S11 , A-C).
TICs from the SEZ contribute to drug resistance
The SEZ and T contained self-renewing TICs suitable for chemo-response assays. These cells are grown in conditions that better preserve the genotype of the original disease (27) and have been proposed for use in high-throughput drug screening (28, 29) . We tested the effects of the oral alkylating agent Temozolomide (TMZ), the current standard of care in GB patients (30) . To facilitate analysis, we assayed methylation in the promoter region of MGMT, a methyltransferase that inhibits the cytotoxic effect of TMZ and is a predictive biomarker in GB (31).
We initially treated TICs isolated from T and SEZ of 7 GB patients with TMZ at maximum concentrations reported for the brain and plasma (50 μM) (32, 33) , but no significant treatment response was observed relative to the corresponding controls (vehicle only). Only sp12 showed a significant response in both T and SEZ (Supplementary Fig. S12 ). We therefore analyzed a set of TICs isolated from T of 20 patients using a dose escalation strategy ranging from 50μM to 2.5mM of TMZ, and found that only 20% of the samples exhibited a significant response at ≥ 500 μM ( Supplementary   Fig. S13, A and B) .
Based on these results we performed cell proliferation assays for TMZ concentrations between 50 μM and 2.5mM on TICs isolated from T and SEZ of the same tumor for 8 patients. We noted that TICs continued to proliferate in the SEZ and T at supra-maximal drug concentrations. We also observed that the response varied between T and SEZ of the same GB ( Fig. 4A and Supplementary Fig. S14A ). Three patterns emerged: differential response between T and SEZ (e.g. sp13, sp20, sp37 and sp42), both T and SEZ respond (e.g. sp17, sp23), neither T nor SEZ respond (e.g. sp14, except at 2.5 mM TMZ for T, and sp52).
To test whether resistance to TMZ was MGMT-dependent, we analyzed the DNA methylation status of the MGMT promoter by pyrosequencing (Supplementary Table S4 ) and methylation-specific PCR (13) ( Supplementary Fig. S15 ) and we found that the results were in agreement except for sp42.
Our PCR analysis revealed that 4/7 paired TICs (sp14, sp23, sp37 and sp52) did not show methylation of the MGMT promoter in either the T or the SEZ consistent with the poor response to TMZ, except for sp23 (T and SEZ) and sp37T. In contrast, sp17, sp20 and sp42 are methylated and showed a better response to TMZ among all the tested TICs with the exception of sp20SEZ and sp42T ( Fig. 4A and Supplementary Fig. S14A ). All together, our results suggest that MGMT methylation status is homogeneous in T and SEZ of the same patients and generally predicts response to TMZ (Supplementary Table S5 ).
We also evaluated the anti-mitotic agent Cisplatin, previously used in GB therapy, and Cediranib, an anti-angiogenic inhibitor of VEGFRs with additional activity against PDGFRB, recently used in clinical trials (34, 35) (Fig. 4B and Supplementary Fig. S14B ). Although anti-angiogenic therapies target the endothelial compartment, it has been reported that VEGFRs are enriched on the surface of TICs from GB (36) . VEGF signals via its endothelial tyrosine kinase receptor 2 (VEGFR2) (35), so we first confirmed that this receptor is expressed in TICs from T and SEZ (Supplementary Fig. S16 ). We next quantified the expression of VEGF and PDGF receptors. No significant difference was present between T and SEZ (no VEGFR1 nor VEGFR3 probe was available in the Illumina arrays) (Supplementary Table S6 ).
Exposure to Cisplatin and Cediranib revealed resistant TICs in T and SEZ together with a heterogeneous response profile ( Fig. 4B and Supplementary Fig. S14B ). Whereas sp17 and sp23 showed sensitivity to these treatments in T and SEZ, a significant response was observed only in one of the two regions for sp13, sp20 and sp52 (Fig. 4B) .
The drug response profile of TICs from T and SEZ of the same patients emphasizes their potential utility in drug development compared to standard glioma cell lines e.g. U87 and human fetal neural stem cells (HFNSCs). U87 significantly responded to treatment with TMZ, Cisplatin and Cediranib whereas two HFNSCs lines (HFNSC and HFNSC1) were resistant to TMZ, as previously reported (37) and to Cisplatin and Cediranib ( Supplementary Fig. S17 ).
Phylogenetic reconstruction suggests different patterns of GB evolution involving SEZ malignant cells
Our genomic and chemo-response assays data show that the SEZ harbors malignant cells that contribute to tumor growth and murine models of GB indicate that the SEZ is enriched for tumor ancestors (2, (38) (39) (40) . However, this has not been confirmed in GB patients. We analyzed SEZ and T samples to determine if tumor cells grow out of the SEZ or into the SEZ. We reconstructed tumor ancestral trees in 8 patients, using several genomic measurements derived from multiple spatially separated samples taken from the GB mass (T1-T6) and SEZ. We have previously employed this approach to describe intra-tumor heterogeneity in T and infer tumor evolution (7) and we now used FGMS to position the SEZ. In particular, we reconstructed phylogeny based on genome-wide DNA copy number (41) . In an independent assay, we exploited the observation that cells record their ancestral history in the form of neutral DNA methylation patterns (42, 43) . This analysis is not biased by the presence of non-neoplastic cells as only highly proliferative tissues accumulate sufficient methylation events (tumors and colonic epithelium) (44) (Fig. 5A) . We first validated the molecular clock loci chosen for this analysis (Fig. 5, B and C, top) and then calculated the normal cell content in SEZ and T. The values of cellularity indicate no significant difference (Fig. 5, B and C, bottom) .
These orthogonal techniques yielded highly concordant phylogenies: in sp52, sp54, sp56 and sp57, the SEZ harbors tumor precursor cells that gave rise to the GB mass (Fig. 5D) . In sp42 and sp49, we observed a similar trend although the two methods are not in full agreement (Fig. 5D) . Analysis of sp55 and sp58 suggests a different pattern of evolution and emphasizes the heterogeneous nature of GB (Fig.   5D ). Taken together, these data suggest that the SEZ contains a reservoir of malignant cells that are either tumor precursor clones or clones generated during GB evolution.
Discussion
Our comprehensive phenotypic, genomic and functional analysis reveals residual disease in the SEZ of GB patients (Fig. 1A and Supplementary Fig. S1, A and B) . TICs are present in T and SEZ of the same GBs ( Fig. 3C and Supplementary Fig. S10 ) and show differential patterns of therapeutic responsiveness and drug resistance (Fig. 4, A and B and Supplementary Fig. S14, A and B) , suggesting that the SEZ should be considered as a novel potential therapeutic target in a subset of GB patients. This is confirmed by phylogenetic reconstruction showing different patterns of tumor evolution with the SEZ harboring precursor clones or clones generated during the GB growth (Fig. 5D ).
Gene expression profiling of SEZ reveals that different GB subtypes (6) are present within the same patient. The SEZ is predominantly Mesenchymal (7 patients) or Classical (2 patients). T is more diverse, with representation from all four subtypes (Fig. 2D) . Thus it is possible to envisage a spectrum of expression patterns with Mesenchymal/Classical representing proliferative diversification at the heart of the tumor.
Previous reports suggested that proximity to the SEZ predicts a multifocal tumor phenotype and recurrences that arise at locations distant from the initial lesion (45) . More recently it has also been reported that contact of the tumor mass with the SEZ correlates with shorter survival (46) . To explore this, we isolated TICs from T and SEZ of the same patients. TICs have been described in human GB but no analysis based on FGMS has been performed. Our results show that in vivo both T-and SEZderived cells generated tumors, however cells from T are more tumorigenic in comparison to the SEZ in agreement with the CNAs of the patient samples showing a trend towards a smaller number of aberrations in the SEZ. These data suggest that the tumorigenic potential is exacerbated when increased genetic alterations are acquired by the cancer genome in line with previous reports (47, 48) .
Since genomic and phenotypic analyses suggest that the SEZ harbors tumor cells, it is crucial to investigate whether there are differences in response to therapy in cells isolated from this region. It has been previously shown that patient-derived TICs accurately represent parent disease (27) and have potential application in high-throughput drug screening (28, 29) . Our data reveal that TICs from T and SEZ of the same GBs show different patterns of response to therapies that represent the current standard of care (Fig. 4, A and B, Supplementary Fig. S14 , A and B and Supplementary Table S5) .
This suggests that they should be targeted using different approaches. Our results also reveal that a clinically significant fraction of cells is resistant to current treatments. This is consistent with murine data (3) indicating that multi-modal stratified approaches will be essential to improve therapeutic responsiveness.
GB evolves by following poorly understood spatial and temporal dynamics arising from cells of origin that are yet to be defined. The presence of malignant cells in the SEZ suggests two different scenarios of evolution with the GB growing into the SEZ or out of this region. Our phylogenetic data indicate that in 4/8 patients a pool of malignant precursor clones evolved in the SEZ (Fig. 5D) . Given the presence of neural stem cells in the adult human SEZ (49) , it has been suggested that GB is derived from those cells (50) . This concept has been investigated in mouse models (2, (38) (39) (40) , but until now there has been no direct evidence of the contribution of SEZ cells in human gliomagenesis. We show that the SEZ is a reservoir of disease and could be targeted therapeutically. Consistent with this, preliminary evidence suggest that irradiation of the SEZ in GB patients is associated with improved progression-free survival (51, 52) .
In summary, we present a phenotypic, genomic and functional analysis of residual disease in human GB ( Supplementary Fig. S18, A and B) . Our approach together with FGMS provides a coherent strategy for interrogating the mechanistic basis of clinical heterogeneity in future studies. This is likely to further refine our understanding of the complex molecular landscape of GB, resulting in improved therapeutic strategies specifically aimed at targeting the SEZ.
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